After Hours Summary: Retailers under pressure after Macy's / Kohl's holiday sales updates, MG -9% following earningsAfter Hours Gainers:
Companies trading higher in after hours in reaction to news/guidance: ALXN +6.4% (files previously delayed Form 10-Q; Audit / Finance Committee concluded that the previously issued financial results do not require restatement), ARNA +4.7% (sells all of its rights to develop and market lorcaserin to Eisai for a reduced amount than previously announced; enters into equity distribution agreement to sell & issue $50 mln in shares of common stock), RT +4.5% (continued strength), SGYP +2.5% (initiated with an Outperform at Oppenheimer), GPRO +1% (confirmed drone Karma set to re-launch in 2017), ACHC +0.9% (after closing near highs of the day +9%), AR +0.7% (capital budget for 2017 is $1.5 billion; Net production is expected to average 2,160 to 2,250 MMcfe/d in 2017, representing year-over-year growth of 20% to 25% relative to 2016 guidance)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: KSS -14.7% (lowers FY17 guidance to $3.60-3.65 from $3.80-4.00 vs $3.93 Capital IQ Consensus Estimate; Nov-Dec comps -2.1%), M -10%, (Macy's lowers FY17 EPS; comparable sales on an owned plus licensed basis declined by 2.1 percent in the months of November and December 2016; announces actions to streamline store portfolio, intensify cost efficiency efforts and execute real estate strategy), MG -9.3%, MC -4% (sees Q4 revs above consensus; raises dividend to $0.37/share from $0.32/share; commenced public offering of 5,000,000 shares of Class A common stock), SONC -0.7%
Companies trading lower in after hours in reaction to news: AEZS -38.4% (reports the confirmatory Phase 3 clinical trial of Macrilen (macimorelin) failed to achieve its objective of validating a single oral dose of macimorelin for the evaluation of growth hormone deficiency in adults), HLX -9.7% (Helix Energy commences public offering of 21 mln shares of common stock; discloses impairment charge and delayed in-service for Siem Helix 1 update), HRTX -8.3% (announces 'positive' topline results from its Phase 2 study of HTX-011 in subjects undergoing abdominoplasty; 'demonstrated statistically significant reductions in both pain intensity and the use of opioid rescue medications through 96 hours following surgery'), KNOP -5.4% (prices offering of 2.5 mln common units, representing limited partner interests for total gross proceeds of approx $56.1 mln), OREX -3.8% (after 64% move higher on Wednesday), SHLD -3.5% (after closing near highs of the day +7%), HPP -0.7% (announced offering of 18,673,808 shares of common stock pursuant to an effective shelf registration statement), ABT -0.5% (Abbott Labs completes acquisiton of St. Jude Medical; S&P lowered rating),, KRC -3.1% (commences 3.5 mln common stock offering)
Retail names lower on KSS / M guidance: JWN -5.2%, JCP -4.6%, DDS -3.9%, SHLD -3.5%